Skip to main content
Yazan Madanat, MD, Internal Medicine, Dallas, TX

Yazan Madanat MD

Internal Medicine•Dallas, TX

Hematology/Oncology

Assistant Professor of Medicine Director of MDS Clinic UTSW Simmons Comprehensive Cancer Center

Join to View Full Profile

  • 5323 Harry Hines BoulevardDallas, TX 75390

  • Phone+1 214-645-4673

  • Fax+1 214-645-2661

Dr. Madanat is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Madanat's Full ProfileAlready have an account?

Education & Training

  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2016 - 2019
  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationResidency, Internal Medicine, 2013 - 2016
  • University of Jordan Faculty of Medicine
    University of Jordan Faculty of MedicineClass of 2011

Certifications & Licensure

  • TX State Medical License
    TX State Medical License Active through 2027
  • OH State Medical License
    OH State Medical License 2013 - 2021
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Hematology
    American Board of Internal Medicine Hematology
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Abstracts/Posters

  • Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia Patients at First Relapse: A Multi-Center Outcomes Analysis
    Yazan F. Madanat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
    Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative NeoplasmsMarch 18th, 2019
  • ASH 2018: Dec 1-4
    ASH 2018: Dec 1-4December 1st, 2017

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Yazan Madanat, Dr. Yazan Madanat, MD, Dr. Y Madanat